JP2023526328A5 - - Google Patents
Info
- Publication number
- JP2023526328A5 JP2023526328A5 JP2022569509A JP2022569509A JP2023526328A5 JP 2023526328 A5 JP2023526328 A5 JP 2023526328A5 JP 2022569509 A JP2022569509 A JP 2022569509A JP 2022569509 A JP2022569509 A JP 2022569509A JP 2023526328 A5 JP2023526328 A5 JP 2023526328A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- riz2
- composition according
- sequence
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063024624P | 2020-05-14 | 2020-05-14 | |
| US63/024,624 | 2020-05-14 | ||
| PCT/US2021/032311 WO2021231771A2 (en) | 2020-05-14 | 2021-05-13 | CANCER TREATMENT USING siRNA TO MODULATE EXPRESSION OF PRDM2/RIZ PROTEIN |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526328A JP2023526328A (ja) | 2023-06-21 |
| JP2023526328A5 true JP2023526328A5 (https=) | 2024-05-17 |
Family
ID=78525067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022569509A Pending JP2023526328A (ja) | 2020-05-14 | 2021-05-13 | ｓｉＲＮＡを使用してＰＲＤＭ２／ＲＩＺタンパク質の発現を調節するがん治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12012597B2 (https=) |
| EP (1) | EP4150093A4 (https=) |
| JP (1) | JP2023526328A (https=) |
| CN (1) | CN116113421A (https=) |
| WO (1) | WO2021231771A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116113421A (zh) | 2020-05-14 | 2023-05-12 | 阿莱兹精准医疗公司 | 使用siRNA调节PRDM2/RIZ蛋白表达的癌症治疗 |
| WO2024151745A2 (en) * | 2023-01-10 | 2024-07-18 | Ariz Precision Medicine, Inc. | Targeted anti-prdm compositions and uses thereof |
| CN119405814A (zh) * | 2024-12-18 | 2025-02-11 | 青岛大学附属医院 | Eno1作为靶点在制备治疗膀胱癌的药物组合物中的用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5831008A (en) * | 1994-08-18 | 1998-11-03 | La Jolla Cancer Research Foundation | Retinoblastoma protein-interacting zinc finger proteins |
| AR020078A1 (es) | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
| US6989245B2 (en) * | 2001-05-11 | 2006-01-24 | The Burnham Institute | Screening, diagnostic and therapeutic methods relating to RIZ |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US7439208B2 (en) | 2003-12-01 | 2008-10-21 | Superconductor Technologies, Inc. | Growth of in-situ thin films by reactive evaporation |
| US20050244851A1 (en) | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
| EP1737879B1 (en) * | 2004-04-19 | 2012-10-10 | Archemix LLC | Aptamer-mediated intracellular delivery of therapeutic oligonucleotides |
| JP4352976B2 (ja) | 2004-04-20 | 2009-10-28 | 株式会社日立製作所 | 受信装置及び受信方法 |
| WO2005116204A1 (ja) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| AU2005250464B2 (en) | 2004-06-01 | 2010-10-07 | The Penn State Research Foundation | Unagglomerated core/shell nanocomposite particles |
| US8603991B2 (en) * | 2005-11-18 | 2013-12-10 | Gradalis, Inc. | Individualized cancer therapy |
| JP5219818B2 (ja) | 2006-09-27 | 2013-06-26 | 今井浩三 | 乳癌および卵巣癌の治療薬、検出方法ならびに検出用キット |
| US8771741B2 (en) | 2009-01-23 | 2014-07-08 | The Penn State Research Foundation | In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles |
| WO2011050178A2 (en) | 2009-10-21 | 2011-04-28 | Lonnie Bookbinder | Targeted prdm gene or protein modulation therapeutic agents |
| WO2011057216A1 (en) | 2009-11-06 | 2011-05-12 | The Pennsylvania State Research Foundation | Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo |
| CA2800065A1 (en) | 2010-05-21 | 2011-11-24 | Peptimed, Inc. | Reagents and methods for treating cancer |
| BR112013010911A2 (pt) | 2010-11-01 | 2017-05-02 | Peptimed Inc | composições de um sistema à base de peptídeo para direcionamento para céllas específicas |
| US10226424B2 (en) | 2012-08-12 | 2019-03-12 | Mylisa Parette | Therapeutic calcium phosphate nanoparticle incorporating siRNA useful in treating disease |
| JP6683986B2 (ja) | 2013-07-10 | 2020-04-22 | 国立大学法人 東京大学 | がん幹細胞分子マーカー |
| JP2016529257A (ja) * | 2013-08-16 | 2016-09-23 | オハイオ ステート イノベーション ファウンデーション | Ｄｎａメチル化を調節する組成物及び方法 |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US10111898B2 (en) | 2014-08-27 | 2018-10-30 | Peptimed, Inc. | Anti-tumor compositions and methods |
| WO2016065273A1 (en) | 2014-10-24 | 2016-04-28 | The University Of Chicago | Heat-inducible self-assembling protein domains |
| US20180291400A1 (en) * | 2015-10-09 | 2018-10-11 | Children's Medical Center Corporation | Methods and compositions to increase human somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation, and derivation of human nt-esc |
| JP2022545055A (ja) | 2019-07-09 | 2022-10-25 | アライズ プレシジョン メディシン，インク． | ＰＲＤＭ１４タンパク質の発現をダウンレギュレートする標的化ｓｉＲＮＡ製剤を使用する癌処置 |
| CN116113421A (zh) | 2020-05-14 | 2023-05-12 | 阿莱兹精准医疗公司 | 使用siRNA调节PRDM2/RIZ蛋白表达的癌症治疗 |
-
2021
- 2021-05-13 CN CN202180047817.2A patent/CN116113421A/zh active Pending
- 2021-05-13 EP EP21804152.3A patent/EP4150093A4/en active Pending
- 2021-05-13 JP JP2022569509A patent/JP2023526328A/ja active Pending
- 2021-05-13 WO PCT/US2021/032311 patent/WO2021231771A2/en not_active Ceased
-
2022
- 2022-09-15 US US17/945,739 patent/US12012597B2/en active Active
-
2024
- 2024-04-23 US US18/643,535 patent/US20240360445A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10550391B2 (en) | Organic compositions to treat beta-ENaC-related diseases | |
| JP2022526419A (ja) | 中枢神経系における遺伝子発現を阻害するための組成物及び方法 | |
| CN1703229B (zh) | 治疗前列腺和其他癌的组合物和其制备药物的用途 | |
| JP2023526328A5 (https=) | ||
| JP2023539341A5 (https=) | ||
| US20220143197A1 (en) | siRNA Inhibition Of Human Antigen R Expression For Treatment of Cancer | |
| US20220267775A1 (en) | CANCER TREATMENT USING TARGETED siRNA PHARMACEUTICAL FORMULATIONS TO DOWNREGULATE EXPRESSION OF PRDM14 PROTEIN | |
| CN114585633A (zh) | 寡核苷酸缀合物组合物和使用方法 | |
| US20240360445A1 (en) | CANCER TREATMENT USING siRNA TO MODULATE EXPRESSION OF PRDM2/RIZ PROTEIN | |
| US11667920B2 (en) | Methods for treating brain injury | |
| Matsui et al. | Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier | |
| JP2020532958A5 (https=) | ||
| EP3322423A1 (en) | Micro-rna for the treatment of malignant solid tumors and metastasis | |
| KR20260005402A (ko) | 암 치료를 위한 조성물 및 방법 | |
| WO2025103391A1 (zh) | 用于抑制lpa的基因表达的sirna，含其的组合物及其用途 | |
| EP3902917A2 (en) | Compositions and methods for treating cancer | |
| WO2019107487A1 (ja) | マイクロｒｎａ及びその誘導体を有効成分とする医薬組成物 | |
| CN112654706B (zh) | 靶向淋巴细胞活化基因3(lag-3)的核酸适体及其用途 | |
| US20250297249A1 (en) | Antisense oligonucleotide complex | |
| HK40076806B (zh) | 使用靶向的sirna药物制剂下调prdm14蛋白质的表达的癌症治疗 | |
| WO2025041340A1 (ja) | 二重特異性核酸 | |
| WO2025259875A1 (en) | Novel antibody oligonucleotide drug conjugates containing gemcitibine for pharmaceutical compositions and related methods of use and treatment | |
| JP2026513654A (ja) | メラノサイト性疾患の治療方法 | |
| HK40076806A (en) | Cancer treatment using targeted sirna pharmaceutical formulations to downregulate expression of prdm14 protein |